A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Vitiligo (Active and Stable)
Condition: Non-segmental Vitiligo (Both Active and Stable Vitiligo) Interventions: Drug: Ritlecitinib; Drug: Placebo Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2022 Category: Research Source Type: clinical trials
